Skip Navigation

European Heart Journal 2000 21(23):1928-1936; doi:10.1053/euhj.2000.2240
Copyright © 2000 by the European Society of Cardiology.
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Menon, V
Right arrow Articles by Ohman, E.M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Menon, V
Right arrow Articles by Ohman, E.M
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Lack of progress in cardiogenic shock: lessons from the GUSTO trials

V Menona,f1, J.S Hochmana, A Stebbinsb, M Pfistererc, J Cold, R.D Andersonb, D Hasdaie, D.R Holmes, Jre, E.R Batesf, E.J Topolg, R.M Califfb and E.M Ohmanb

a Division of Cardiology, St. Luke's-Roosevelt Hospital Center, Columbia University, New York, NY, U.S.A.
b Division of Cardiology, Duke University Medical Center, Durham, NC, U.S.A.
c Division of Cardiology, University Hospital, Basel, Switzerland
d Division of Cardiology, Cliniques Universitaires, Brussels, Belgium
e Division of Cardiology, Mayo Clinic, Rochester, MN, U.S.A.
f Division of Cardiology, University of Michigan Medical Center, Ann Arbor, MI, U.S.A.
g Division of Cardiology, Cleveland Clinic Foundation, Cleveland, OH, U.S.A.

Received April 4, 2000; accepted April 5, 2000

Abstract

Aims We used the GUSTO-I and GUSTO-III databases to evaluate our performance in treating cardiogenic shock patients over much of the 1990s.

Methods and Results GUSTO-I (1990–1993) and GUSTO-III (1995–1997) prospectively identified all patients with cardiogenic shock complicating acute myocardial infarction. Demographics, clinical presentation and outcomes for cardiogenic shock patients in the two trials were compared. Only patients enrolled with cardiogenic shock in countries common to both trials were included in these analysis. The 695 patients with cardiogenic shock in GUSTO-III were compared with the 2814 patients with cardiogenic shock in GUSTO-I. GUSTO-III patients were older (P=0·0001) and more likely to be diabetic (P=0·009) and hypertensive (P=0·025). They had a higher Killip class (P=0·002) and significantly greater index anterior infarction than cardiogenic shock patients enrolled in GUSTO-I. Time to treatment, presentation heart rate, and diastolic blood pressure were similar; however, systolic blood pressure at presentation was higher among GUSTO-III patients (P=0·002). Rates of coronary angiography, pulmonary artery catheterization, and mechanical ventilation declined in GUSTO-III compared with GUSTO-I (P=0·001); rates of angioplasty and bypass surgery were similar. Cardiogenic shock mortality in GUSTO-III was significantly higher than in GUSTO-I (62 vs 54%,P =0·001), as were rates of reinfarction (14 vs 11%, P=0·013) and recurrent ischaemia (35 vs 27%, P=0·00001). Mortality at non-U.S. sites (68 and 64%) was higher than at U.S. sites (53 and 50%) in both GUSTO-I and GUSTO-III studies, respectively. Angioplasty, bypass surgery, and balloon pump rates were lower for non-U.S. patients.

Conclusions Cardiogenic shock continues to be associated with high mortality in thrombolytic-treated patients. Lower mortality observed in the U.S.A. supports consideration for percutaneous and surgical revascularization.

Key Words: shock, thrombolysis, myocardial infarction, mortality

f1 Correspondence: Venu Menon, MD, FACC, Assistant Director-Cardiac Research, Cardiac Study Center, St. Luke's-Roosevelt Hospital Center, 1111 Amsterdam Avenue, New York, NY 10025, U.S.A.

References

  1. N Engl J Med. 1993;329:673–682[Abstract/Free Full Text]
  2. N Engl J Med. 1993;329:1615–1622[Abstract/Free Full Text]
  3. Simes RJ, Topol EJ, Holmes DR. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: importance of early and complete infarct artery reperfusion. Circulation. 1995;91:1923–1928[Abstract/Free Full Text]
  4. Meinertz T, Kasper W, Schumacher M. The German multi-center trial of anisoylated streptokinase activator complex versus heparin for acute myocardial infarction. Am J Cardiol. 1988;62:347–351[CrossRef][Web of Science][Medline]
  5. Wilcox RG, Olsson CG, von der Lippe G. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction (ASSET). Lancet. 1988;ii:525–530
  6. Holmes DR Jr, Bates ER, Kleiman NS. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. J Am Coll Cardiol. 1995;26:668–674[Abstract]
  7. Col NF, Gurentz JH, Alpert JS, Goldberg RJ. Frequency of inclusion of patients with cardiogenic shock in clinical trials. Am J Cardiol. 1994;73:149–157[CrossRef][Web of Science][Medline]
  8. N Engl J Med. 1997;337:1118–1123[Abstract/Free Full Text]
  9. Lancet. 1992;339:753–770[Web of Science][Medline]
  10. Lancet. 1986;i:397–402
  11. Granger CB, Hirsch J, Califf RM. Activated partial thromboplastin time and outcomes after thrombolytic therapy for acute myocardial infarction; results from the GUSTO-I trial. Circulation. 1996;93:870–878[Abstract/Free Full Text]
  12. Lee KL, Woodlief LH, Topol EJ. Predictors of 30 day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-1 Investigators. Circulation. 1995;91:1659–1668[Abstract/Free Full Text]
  13. Lancet. 1994;343:311–322[CrossRef][Web of Science][Medline]
  14. Goldberg RJ, Samad NA, Yarzebski J, Gurwitz J, Bigelow C, Gore JM. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med. 1999;340:1162–1168[Abstract/Free Full Text]
  15. Holmes DR Jr, Califf RM, Van de Werf. Differences in countries use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction. Lancet. 1997;349:75–78[CrossRef][Web of Science][Medline]
  16. Connors AF, Speroff T, Dawson NV. The effectiveness of right heart catheterization in the initial care of critically ill patients. J Am Med Assoc. 1996;18:889–897
  17. Prewitt RM, Gu S, Schick U, Ducas J. Intraaortic balloon counterpulsation enhances coronary thrombolysis induced by intravenous administration of a thrombolytic agent. J Am Coll Cardiol. 1994;23:784–788
  18. Gurbel PA, Anderson RD, MacCord CS. Arterial diastolic blood pressure augmentation by intraaortic balloon counterpulsation enhances the onset of coronary reperfusion by thrombolytic therapy. Circulation. 1994;89:361–365[Abstract/Free Full Text]
  19. Anderson RD, Ohman EM, Holmes DR Jr. Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I study. J Am Coll Cardiol. 1997;30:708–715[Abstract]
  20. Waksman R, Weiss AT, Gotsman MS. Intraaortic balloon counterpulsation improves survival in cardiogenic shock complicating acute myocardial infarction. Eur Heart J. 1993;14:71–74[Abstract/Free Full Text]
  21. Hochman JS, Boland J, Sleeper LA. Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an international registry. Circulation. 1995;91:873–881[Abstract/Free Full Text]
  22. Lancet. 1990;336:71–75[CrossRef][Web of Science][Medline]
  23. Hochman JS, Sleeper LA, Webb JG. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med. 1999;341:625–634[Abstract/Free Full Text]
  24. Hochman JS, Sleeper LA, Webb J. Effect of early revascularization for cardiogenic shock on 1 year mortality; the SHOCK trial results (Abstr). Circulation. 1999;100:I-369

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ChestHome page
R. V. Jeger, A. M. Lowe, C. E. Buller, M. E. Pfisterer, V. Dzavik, J. G. Webb, J. S. Hochman, U. P. Jorde, and for the SHOCK Investigators
Hemodynamic Parameters Are Prognostically Important in Cardiogenic Shock But Similar Following Early Revascularization or Initial Medical Stabilization: A Report From the SHOCK Trial
Chest, December 1, 2007; 132(6): 1794 - 1803.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. Fincke, J. S. Hochman, A. M. Lowe, V. Menon, J. N. Slater, J. G. Webb, T. H. LeJemtel, G. Cotter, and SHOCK Investigators
Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: A report from the SHOCK trial registry
J. Am. Coll. Cardiol., July 21, 2004; 44(2): 340 - 348.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
D.R Holmes
The final common pathway
Eur. Heart J., February 1, 2003; 24(3): 214 - 216.
[Full Text] [PDF]

Home page
 HeartHome page
V. Menon and J. S Hochman
MANAGEMENT OF CARDIOGENIC SHOCK COMPLICATING ACUTE MYOCARDIAL INFARCTION
Heart, December 1, 2002; 88(5): 531 - 537.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. R. Thiemann
Primary angioplasty for elderly patients with myocardial infarction: Theory, practice and possibilities
J. Am. Coll. Cardiol., June 5, 2002; 39(11): 1729 - 1732.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
L Carnendran, R Abboud, L.A Sleeper, R Gurunathan, J.G Webb, V Menon, V Dzavik, T Cocke, J.S Hochman, and for the SHOCK Investigators
Trends in cardiogenic shock: report from the SHOCK Study
Eur. Heart J., March 2, 2001; 22(6): 472 - 478.
[Abstract] [PDF]

Home page
 Eur Heart JHome page
J. Dens and F. van de Werf
Cardiogenic shock: a call for aggressiveness
Eur. Heart J., December 1, 2000; 21(23): 1903 - 1904.
[PDF]

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Menon, V
Right arrow Articles by Ohman, E.M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Menon, V
Right arrow Articles by Ohman, E.M
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?